HBV
Hepatitis B virus
HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.
All Product Categories
-
HBV Related Products (378)
Related Products (378)
-
Antibodies (2)
-
Taurolithocholic acid-d5
0 ImagesCat. No.: HY-113308SCAS No.: 1265681-64-8Taurolithocholic acid-d5 is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
-
Dimethyl biphenyl-4,4'-dicarboxylate-d8
0 ImagesCat. No.: HY-128854SCAS No.: 1219803-50-5Dimethyl biphenyl-4,4'-dicarboxylate-d8 is the d8-labeled Dimethyl biphenyl-4,4'-dicarboxylate (HY-128854). Dimethyl biphenyl-4,4'-dicarboxylate (Biphenyl dimethyl dicarboxylate) is a hepatoprotective agent. Dimethyl biphenyl-4,4'-dicarboxylate stimulates the Jak/Stat signaling pathway and induces the expression of IFN-α-stimulated genes, particularly 6-16 and ISG12. Dimethyl biphenyl-4,4'-dicarboxylate inhibits the replication of pregenomic RNA and HBeAg. Polymer micelles loaded with Dimethyl biphenyl-4,4'-dicarboxylate can serve as carriers for the compound. Dimethyl biphenyl-4,4'-dicarboxylate can be used as an auxiliary improving agent for chronic hepatitis. Dimethyl biphenyl-4,4'-dicarboxylate is applicable to research related to chronic hepatitis B.
-
Lamivudine-15N,d2
0 ImagesCat. No.: HY-B0250SSynonyms: BCH-189-15N,d2Lamivudine-15N,d2 is 15N and deuterated labeled Lamivudine (HY-B0250). Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.
-
L-Fd4A
0 ImagesCat. No.: HY-148172CAS No.: 210474-65-0
-
Ozisiran sodium
0 ImagesCat. No.: HY-177654A
-
Di-Val-L-dC
0 ImagesCat. No.: HY-106205CAS No.: 380886-96-4Di-Val-L-dC, a prodrug of L-deoxycytidine, is a selective and specific anti-HBV agent.
-
Hepatitis b virus pre-s region (120-145)
0 ImagesCat. No.: HY-P4043CAS No.: 104504-34-9Hepatitis b virus pre-s region (120-145) is a preS2 peptide that inhibits the binding of single-chain Fv fragment (scFv) or IgG to r-HBsAg.
-
Clevudine triphosphate
0 ImagesCat. No.: HY-125719CAS No.: 174625-00-4Synonyms: L-FMAU-TPClevudine triphosphate is a thymidine analog. Clevudine triphosphate has anti-human hepatitis B virus (HBV) activity.
-
L-2'-Fd4C
0 ImagesCat. No.: HY-148171CAS No.: 221662-50-6
-
HBV-IN-7
0 ImagesCat. No.: HY-145050CAS No.: 2724224-49-9HBV-IN-7 is a potent HBV inhibitor with an EC50 of 7 nM (WO2021213445A1, compound 5).
-
HBV-IN-8
0 ImagesCat. No.: HY-145051CAS No.: 2724224-57-9HBV-IN-8 is a potent HBV inhibitor with an EC50 of 287.9 nM (WO2021213445A1, compound 13).
-
Tenofovir (Standard)
0 ImagesSynonyms: GS 1278 (Standard); PMPA (Standard)
-
HBV-IN-39-d3
0 ImagesCat. No.: HY-156703SCAS No.: 2173356-23-3HBV-IN-39-d3 (Example 14) is a deuterated HBV-IN-39 (Example 13). HBV-IN-39 is an HBV inhibitor. HBV-IN-39-d3 has better oral bioavailability than HBV-IN-39.
-
(5S,8R)-HBV-IN-10
0 ImagesCat. No.: HY-145053ACAS No.: 2716907-15-0(5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6.
